MetaCap

YD Bio Limited (YDES)

NASDAQ: YDESHealth CareMedical SpecialitiesUSD

4.83+0.27 (+5.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

YDES stock chart

Technical analysis

Key statistics

All statistics
Market cap
$342.12M
EPS (TTM)
-$0.04
52-week range
1.70 – 15.72
Day range
4.36 – 4.95
Volume / Avg
29.79K / 309.22K
Beta
—

52-week range

$1.70$15.72

YDES stock today

YD Bio (YDES) closed at $4.83 on Nov 20, up 5.92% (+$0.27), versus the S&P 500's 3.70% decline. Trading was light, with 29.79K shares changing hands, about 10% of the average daily volume. Shares are 69.3% below their 52-week high of $15.72, set on Dec 8, 2025 and 184.1% above the 52-week low of $1.70, in the middle of the past year's range.

YDES is down 60.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 42.8%. YD Bio has posted a net loss over the last twelve months (EPS of -$0.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About YD Bio

Company profile

YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses.

Industry
Medical Specialities
CEO
Dr. Ethan Shen Ph.D.
Headquarters
Taipei
Employees
13

Financial highlights

Full financials

In fiscal 2025, YD Bio generated $596,817 in revenue, up 16.9% from fiscal 2024, its 2nd consecutive year of revenue growth. YD Bio reported a net loss of $8.3 million, compared with a loss of $1.4 million a year earlier. Gross margin was 28.1% (down from 30.4%) and operating margin -883.3%.

YD Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$596.82K$510.36K$350.13K
Growth+16.94%+45.76%—
Net income$-8.31M$-1.41M$13.56K
EPS (diluted)$-0.12$-0.02$0.00

YDES news

All YDES news

YD Bio peers

Health Care sector
YDES peer companies
CompanyPrice% ChgMarket capCompare
TLSITriSalus Life Sciences Inc.2.32+6.67%$143.14Mvs YDES
BNRBurning Rock Biotech Limited ADR13.24-0.60%$139.63Mvs YDES
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs YDES
XGNExagen Inc.3.61-5.00%$92.10Mvs YDES
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs YDES
SERASera Prognostics Inc. Class A1.81-4.23%$71.98Mvs YDES
FLGTFulgent Genetics Inc.24.12-2.66%$673.89Mvs YDES
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs YDES

Indexes, lists and sector

YD Bio stock FAQ

What is YD Bio's stock price today?

YDES last traded at $4.83 as of Nov 20, 4:00 PM EST, up 5.92% on the day. Prices are delayed at least 15 minutes.

Who is YD Bio's CEO?

Dr. Ethan Shen Ph.D. is the chief executive officer of YD Bio Limited, which has about 13 employees.

What is the YDES 52-week high?

The 52-week high for YDES is $15.72 and the 52-week low is $1.70. The stock is currently 69.3% below its high.

Compare YDES